SMS Pharmaceuticals Ltd reported a significant 80% increase in PAT (Profit After Tax), totaling ₹25.32 crore for Q2 FY26, driven by strong demand, higher revenues, and successful cost management efforts. The company also outlined a ₹280 crore capital expenditure program aimed at enhancing production capacity and expanding R&D operations by 2026.